N

Nkarta
D

NKTX

2.99000
USD
0.38
(14.34%)
Market Closed
Volume
39,442
EPS
-2
Div Yield
-
P/E
-2
Market Cap
211,000,574
OverviewSignalsIdeasNews
Related Instruments
    A
    ADCT
    -0.27000
    (-10.19%)
    2.38000 USD
    A
    ASND
    2.160
    (1.74%)
    126.510 USD
    C
    CRIS
    -0.04000
    (-1.00%)
    3.96000 USD
    I
    IOVA
    -0.40000
    (-4.65%)
    8.19500 USD
    M
    MGNX
    -0.23000
    (-6.04%)
    3.58000 USD
    N
    NKTR
    -0.11000
    (-9.36%)
    1.06500 USD
    More
News

Title: Nkarta

Sector: Healthcare
Industry: Biotechnology
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.